Plain English Summary
Background and study aims
The NHS spends over £2 billion a year on treating schizophrenia, including expensive in-patient care. Consequently the development of cost-effective psychological therapies for schizophrenia is an NHS priority. Although government guidelines recommend cognitive behavioural therapy (CBT) as a treatment, the NHS struggles to meet this demand. Due to the wide range of presentations associated with a diagnosis of schizophrenia, the relevant CBT training is still generic and lengthy. There is a need for treatment protocols which target specific forms of schizophrenic presentation. These interventions are easier to disseminate within the NHS, and are likely to be more cost-effective. People diagnosed with schizophrenia are particularly likely to have suffered traumatic life events, and up to 40% may suffer from symptoms of posttraumatic stress disorder (PTSD). This ‘co-morbid’ condition is associated with severe symptoms, abusing illicit drugs and alcohol, and frequent hospital admissions. There have been no studies of any treatment for PTSD within this group. As standard CBT for PTSD is considered to be unsuitable for people with schizophrenia, a CBT package has been carefully designed for this purpose. A pilot study suggests a high level of patient acceptability. The potential for benefits in patient wellbeing and reduced healthcare costs suggest that the intervention should be evaluated within an NHS setting. The aim of this study is to test whether CBT, delivered to patients with co-morbid schizophrenia and PTSD, in addition to standard psychiatric care will result in a reduced level of PTSD and psychotic symptoms.
Who can participate?
Patients aged between 18 and 65 diagnosed with schizophrenia and PTSD
What does the study involve?
Participants are randomly allocated to receive either the CBT package or standard psychiatric care. Existing NHS clinicians are trained to conduct the CBT package as part of their routine clinical work. Assessments are carried out at the beginning of the treatment, the end of treatment and after a 6-month follow-up. Levels of symptoms and health care use are compared between the two groups. The acceptability of the intervention to the patients is assessed through an interview conducted at the end of treatment.
What are the possible benefits and risks of participating?
There are no perceived risks, whilst the CBT programme may provide the benefit of a reduction within the symptoms of posttraumatic stress.
Where is the study run from?
University of Reading (UK)
When is the study starting and how long is it expected to run for?
January 2010 to September 2011
Who is funding the study?
National Institute for Health Research (NIHR) (UK)
Who is the main contact?
Dr Craig Steel
Trial website
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
6683
Study information
Scientific title
The acceptability and effectiveness of cognitive behavioural therapy for the treatment of post-traumatic stress disorder within schizophrenia: a randomised interventional treatment trial
Acronym
Study hypothesis
Sixty-two participants who are diagnosed with schizophrenia/schizo-affective disorder/schizophreniform disorder and post-traumatic stress disorder (PTSD) will be randomly allocated to receive either the proposed cognitive behavioural therapy (CBT) package or routine psychiatric care. The CBT package includes 16 sessions to be conducted within a 6-month period. Currently employed NHS clinicians will be trained to conduct the intervention as part of their routine clinical practice. Symptoms and level of use of NHS services will be assessed at baseline (week 0), end of therapy (6 months) and after a 6-month follow-up period (12 months). The primary outcome will be level of PTSD symptoms at end of treatment, as measured by the Clinician Administered PTSD scale (CAPS). Acceptability of the intervention will be assessed through a service-user led interview.
The principal research questions to be addressed:
The main hypothesis to be tested is that CBT, delivered to patients with co-morbid schizophrenia and PTSD, in addition to standard psychiatric care will result in a reduced level of PTSD symptomatology. The subsidiary hypothesis is that reduction in PTSD symptoms will mediate a reduction in psychotic symptomatology and service-use.
Ethics approval
Berkshire Research Ethics Committee (REC), 01/03/2010, ref: 09/H0505/85
Study design
Randomised interventional treatment trial
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Hospitals
Trial type
Treatment
Patient information sheet
Not available in web format, please use the contact details to request a patient information sheet
Condition
Topic: Mental Health Research Network; Subtopic: Schizophrenia; Disease: Schizophrenia, post-traumatic stress disorder (PTSD);
Intervention
The trial compares standard psychiatric care alone with CBT treatment in addition to standard care.
Standard psychiatric care in the UK is based on the care programme approach to case management and includes antipsychotic medication, outpatient and community follow-up, and access to community-based rehabilitative activities such as day centres and drop ins.
CBT intervention consists of several important parts.
1. Establish safety: Issues such as suicidality, self-harming behaviour
Intervention type
Other
Phase
Not Applicable
Drug names
Primary outcome measure
PTSD symptoms, assessed through the Clinician Administered PTSD Scale (CAPS), measured at baseline, 6 months and 12 months
Secondary outcome measures
Post-traumatic Cognitions, assessed using the Post-traumatic Cognitions Inventory (PTCI), measured at baseline, 6 months and 12 months
Overall trial start date
01/01/2010
Overall trial end date
30/09/2011
Reason abandoned (if study stopped)
Eligibility
Participant inclusion criteria
1. Provides consent
2. Current Diagnostic and Statistical Manual, Fourth Edition (DSM-IV) diagnosis of schizophrenia or schizo-affective disorder
3. Present with symptoms consistent with a DSM-IV diagnosis of PTSD
4. Aged between 18 and 65 years, either sex
Participant type
Patient
Age group
Adult
Gender
Both
Target number of participants
Planned Sample Size: 62; UK Sample Size: 62
Participant exclusion criteria
1. Organic disorder
2. Unable to read and write in English
3. Learning disability
Recruitment start date
01/01/2010
Recruitment end date
30/09/2011
Locations
Countries of recruitment
United Kingdom
Trial participating centre
University of Reading
Reading
RG6 6AL
United Kingdom
Sponsor information
Organisation
University of Reading (UK)
Sponsor details
Winnicott Rsearch Unit
School of Psychology
PO Box 238
Reading
RG6 6AL
United Kingdom
Sponsor type
University/education
Website
Funders
Funder type
Government
Funder name
Research for Patient Benefit Programme
Alternative name(s)
NIHR Research for Patient Benefit Programme, RfPB
Funding Body Type
government organisation
Funding Body Subtype
Federal/National Government
Location
United Kingdom
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Basic results (scientific)
Publication list
2017 results in: https://www.ncbi.nlm.nih.gov/pubmed/27650432